Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting.
Comparing the efficacy of different treatments in psychiatry is difficult for many reasons, even when they are investigated in "head-to-head" studies. A consensus meeting was, therefore, held to produce best practice guidelines for such studies. This article presents the conclusions of this consensus and illustrates it using published data in the field of antidepressant treatment of generalized anxiety disorder.
Nutt
D
D
Psychopharmacology Unit, University of Bristol, Bristol, UK. david.j.nutt@bristol.ac.uk
Allgulander
C
C
Lecrubier
Y
Y
Peters
T
T
Wittchen
U
U
D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy*; D003245:Consensus Statements as Topic; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use*; D000068736:Duloxetine Hydrochloride; D019317:Evidence-Based Medicine; D006801:Humans; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride
D000928:Antidepressive Agents; D003511:Cyclohexanols; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes; D000069470:Venlafaxine Hydrochloride